The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective

Acta Neurologica Scandinavica

Volumn 92, Issue 4, 1995, Pages 273-280

  Walker, U A ^a   Byrne, E ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

mitochondrial encephalomyopathies; mitochondrial myopathies; oxidative phosphorylation; riboflavin; thiamine; treatment outcome; ubiquinone; vitamin K

Indexed keywords

ASCORBIC ACID; CHLORAMPHENICOL; COENZYME Q DERIVATIVE; CORTICOSTEROID; DICHLOROACETIC ACID; IDEBENONE; MENADIONE; NICOTINAMIDE; PHYTOMENADIONE; PYRIDOXINE; QUINONE DERIVATIVE; RIBOFLAVIN; SUCCINIC ACID; THIAMINE; UNCLASSIFIED DRUG;

ENCEPHALOMYOPATHY; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; RAT; RESPIRATORY CHAIN; REVIEW; TREATMENT OUTCOME;

BENZOQUINONES; DICHLOROACETATE; DNA, MITOCHONDRIAL; HUMAN; HYPOGLYCEMIC AGENTS; MITOCHONDRIA, MUSCLE; MITOCHONDRIAL ENCEPHALOMYOPATHIES; OXIDATIVE PHOSPHORYLATION; PHYSICAL THERAPY TECHNIQUES; RESPIRATORY TRACT DISEASES; RIBOFLAVIN; SUPPORT, NON-U.S. GOV'T; THIAMINE; UBIQUINONE; VITAMIN K; VITAMINS;

EID: 0029135073     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1995.tb00130.x     Document Type: Review

References (77)

1. Coupling of phosphorylation to electron and hydrogen transfer by a chemiosmotic type of mechanism
2. An auto‐somal dominant locus predisposing to deletions of mitochondrial DNA
3. Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion
4. Deficiency of the human mitochondrial transcription factor h‐mtTFA in infantile mitochondrial myopathy is associated with mtDNA depletion
5. Retitinitis pigmentosa, external ophthalmoplegia and complete heart block
6. Oculocraniosomatic neuromuscular disease with “ragged‐red” fibres
7. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke like episodes: a distinctive clinical syndrome
8. Myoclonus epilepsy associated with red ragged fibres (mitochondrial abnormalities): disease entity or a syndrome? Light and electron microscopic studies of two cases and a review of the literature
9. Mitochondrial encephalomyopathies. [Review]
10. Mitochondrial diseases: genotype versus phenotype
11. The impact of the 25th chromosome on mitochondrial dysfunction in human disease
12. Mitochondrial DNA mutation and the ageing process: bioenergy and pharmacological intervention
13. Lateral diffusion of ubiquinone during electron transfer in phospholipid and ubiquinone‐enriched mitochondrial membranes
14. Antioxidative effect of ubiquinones on mitochondrial membranes
15. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy
16. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q 10 in Kearns‐Sayre syndrome
17. Transfer of exogenous coenzyme Q10 to the inner membrane of heart mitochondria in rats
18. Exogenous coenzyme Q (CoQ) fails to increase CoQ in skeletal muscle of two patients with mitochondrial myopathies
19. Ubide‐carenone in the treatment of mitochondrial myopathies: a multi‐center double‐blind trial
20. Long‐term coenzyme Q10 therapy for a mitochondrial encephalo‐myopathy with cytochrome c oxidase deficiency. A 31P NMR study
21. Treatment of Kearns‐Sayre syndrome with coenzyme Q 10
22. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10
23. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke‐like episodes (MELAS)
24. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies
25. Spontaneous Kearns‐Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip‐replication model and metabolic therapy
26. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy
27. Cardiac transplantation in an incomplete Kearns‐Sayre syndrome with mitochondrial DNA deletion
28. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease
29. Coenzyme Q in serum and muscle of 5 patients with Kearns‐sayre syndrome and 12 patients with ophthalmoplegia plus
30. An early phase I study to determine the tolerance, safety and pharmacokinetics of idebenone following multiple oral doses
31. Inhibition of lipid peroxidation by a novel compound, ibedenone (CV‐2619)
32. Stimulation of respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV‐2619), a new agent improving cerebral metabolism
33. Effects of idebenone on monoamine metabolites in cerebrospinal fluid of patients with cerebro‐vascular dementia
34. [A case of mitochondrial encephalomyopathy with schizophrenic psychosis, dementia and neuroleptic malignant syndrome]. [Japanese]
35. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone
36. Vitamin K and warfarin distribution and metabolism in the warfarin‐resistant rat
37. Fat‐soluble vitamins. Vitamins A, K, and E
38. Effect of menadione on the electron transport pathway of yeast mitochondria
39. Treatment of experimental NADH ubiquinone reductase deficiency with menadione
40. Mechanism of action of the hypoglycemic agent diphenyleneiodonium
41. Oxygen dependence and subcellular partitioning of hepatic menadione‐mediated oxygen uptake
42. 31P‐NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle
43. Treatment of mitochondrial myopathy due to complex III deficiency with vitamins K3 and C: a 31P‐NMR follow‐up study
44. Correction of increased plasma pyruvate and plasma lactate levels using large doses of thiamine in patients with Kearns‐Sayre syndrome
45. Mitochondrial myopathy, cardiomyopathy, lactic acidosis and response to prednisone and thiamine
46. Water‐soluble vitamins. The vitamin B complex and ascorbic acid
47. Biogenesis of flavoprotein and cytochrome components in hepatic mitochondria from riboflavin deficient rats
48. NADH‐CoQ reductase deficient myopathy: successful treatment with riboflavin
49. MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 3 1P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin
50. Treatment of complex I deficiency with riboflavin
51. A mitochondrial myopathy in an infant with lactic acidosis
52. Mitochondrial encephalomyopathy with corticosteroid dependence
53. Mitochondrial encephalomyopathies; a group of neuroniuscular disorders with defects in oxidative metabolism
54. MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission
55. Corticosteroid responsive mitochondrial encephalomyopathy [letter]
56. The treatment of mitochondrial disease
57. Fatal metabolic acidosis, hyperglycemia, and coma after steroid therapy for Kearns‐Sayre syndrome
58. Glucose and amino acid metabolism in perfused skeletal muscle – effect of dichloroacetate
59. Effects of dichloroacetate on the metabolism of glucose, pyruvate, acetate, 3‐hydroxybutyrate and palmitate in rat diaphragm and heart muscle in vitro and on extraction of glucose, lactate, pyruvate and free fatty acids by dog heart in vivo
60. Treatment of lactic acidosis with dichloroacetate
61. Dichloroacetate in the treatment of lactic acidosis
62. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis
63. Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS
64. The effect of an alpha‐ketoglutarate‐pyridoxine complex on human maximal aerobic and anaerobic performance
65. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: A correlated clinical, biochemical, and morphological study
66. Luft's disease. Further biochemical and ultrastructural studies of skeletal muscle in the second case
67. Deficiency of subunits of complex I and mitochondrial encephalomyopathy
68. Cerebral blood flow in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes
69. Cardiomyopathy in the Kearns‐Sayre syndrome
70. Inhalation anaesthesia and the Kearns‐Sayre syndrome
71. Recurrent respiratory insufficiency and depressed ventilatory drive complicating mitochondrial myopathies
72. The presequences of two imported mitochondrial proteins contain information for intracellular and intramitochondrial sorting
73. DNA‐protein conjugates can enter mitochondria via the protein import pathway
74. The potential for gene therapy in Duchenne muscular dystrophy and other genetic muscle diseases
75. Transplantation of adult‐derived my‐oblasts in mice following gene transfer
76. Strategies to achieve targeted gene delivery via the receptor‐mediated endocytosis pathway